Evidence map›Paper›PMID 38519705›Full record

ArticleBritish journal of cancer2024

Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.

Koji Haratani, Atsushi Nakamura, Nobuaki Mamesaya, Kenji Sawa, Yoshimasa Shiraishi, Ryota Saito, Junko Tanizaki, Yosuke Tamura, Akito Hata, Kosuke Tsuruno and 15 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 17 institutions in 1 country.

Koji HarataniDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan. haratani_k@med.kindai.ac.jp.ORCID 0000-0002-1767-6854
Atsushi NakamuraDepartment of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Miyagi, Japan.
Nobuaki MamesayaDivision of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan.
Kenji SawaDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Osaka, Japan.
Yoshimasa ShiraishiDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan.
Ryota SaitoDepartment of Respiratory Medicine, Tohoku University School of Medicine, Sendai, Miyagi, Japan.
Junko TanizakiDivision of Medical Oncology, Kishiwada City Hospital, Kishiwada, Osaka, Japan.
Yosuke TamuraRespiratory Medicine and Thoracic Oncology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Akito HataDivision of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Hyogo, Japan.
Kosuke TsurunoDepartment of Respiratory Medicine, Iizuka Hospital, Iizuka, Fukuoka, Japan.
Tomohiro SakamotoDivision of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Tottori, Japan.
Shunsuke TeraokaInternal Medicine III, Wakayama Medical University, Wakayama, Wakayama, Japan.
Masahide OkiDepartment of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan.
Hiroshi WatanabeDepartment of Respiratory Medicine, Saka General Hospital, Shiogama, Miyagi, Japan.
Takaaki TokitoDivision of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Kenji NagataDepartment of Respiratory Medicine, Itami City Hospital, Itami, Hyogo, Japan.
Takeshi MasudaDepartment of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Hiroshima, Japan.
Yasushi NakamuraDepartment of Pathology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
Kazuko SakaiDepartment of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
Yasutaka ChibaClinical Research Center, Kindai University Hospital, Osaka-Sayama, Osaka, Japan.
Akihiko ItoDepartment of Pathology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.ORCID 0000-0003-1411-4001
Kazuto NishioDepartment of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.ORCID 0000-0002-8275-0846
Nobuyuki YamamotoInternal Medicine III, Wakayama Medical University, Wakayama, Wakayama, Japan.
Kazuhiko NakagawaDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
Hidetoshi HayashiDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.ORCID 0000-0001-8787-5587
Kindai University · JPKindai University Hospital · JPWakayama Medical University · JPAso Iizuka Hospital · JPHiroshima University Hospital · JPItami City Hospital · JPKishiwada City Hospital · JPKobe Medical Center · JPKurume University · JPKyushu University · JPNational Hospital Organization · JPOsaka Metropolitan University · JPOsaka University of Pharmaceutical Sciences · JPSendai Kousei Hospital · JPShizuoka Cancer Center · JPTohoku University · JPTottori University · JP

Funding

AstraZeneca ESR-18-13940
6 · The paper itself

Abstract

backgroundImmune-related adverse events (irAEs) have been found to predict PD-L1 inhibitor efficacy in metastatic NSCLC. However, the relation of irAEs to clinical outcome for nonmetastatic NSCLC has remained unknown.

methodsIn this multicenter prospective study of Stage III NSCLC treated with PACIFIC regimen, the relation of irAEs to PFS was evaluated by 8-week landmark analysis to minimise lead-time bias as well as by multivariable analysis adjusted for baseline factors. irAEs were categorised as mild or nonmild according to whether they were treated with systemic steroid.

resultsMedian PFS was 16.0 months, not reached, and 9.7 months for patients without (85 cases) or with mild (21 cases) or nonmild (21 cases) irAEs, respectively. Multivariable analysis indicated that nonmild irAEs were associated with poor PFS, with HRs of 3.86 (95% CI, 1.31-11.38) compared with no irAEs and 11.58 (95% CI, 2.11-63.63) compared with mild irAEs. This pattern was consistent after irAE grade, the number of durvalumab doses and immune profiles (PD-L1 score, CD8

conclusionsThe development of mild irAEs might predict a better survival outcome, whereas immunosuppressive steroid-treated irAEs were associated with a worse outcome, regardless of baseline clinical and immune profiles.

Indexed as

Antibodies, MonoclonalCarcinoma, Non-Small-Cell LungChemoradiotherapyLung NeoplasmsAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalFemaleHumansMaleMiddle AgedNeoplasm StagingProgression-Free SurvivalProspective StudiesAntibodies, MonoclonalAntineoplastic Agents, Immunologicaldurvalumab

Identifiers

PMID38519705
PMCPMC11130152
OpenAlexW4393082626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.